PURPOSE: Complement may play a role in the clinical response to rituximab and other monoclonal antibody-based therapies of cancer. The purpose of this study was to explore the relationship between the C1qA([276]) polymorphism and the clinical response to rituximab in patients with follicular lymphoma. EXPERIMENTAL DESIGN: Genotyping for C1qA([276A/G]) was done in 133 subjects with follicular lymphoma treated with single-agent rituximab, and correlation with clinical response was done using Cox regression analysis. RESULTS: Prolonged remission was observed among subjects that responded clinically to rituximab therapy and were carriers of the A allele compared with homozygous G subjects. Homozygous G subjects had a time to progression of 282 days, whereas A-allele carriers had a time to progression of 708 days [hazard ratio, (HR), 2.5; 95% confidence interval (95% CI), 2.0-3.1; P = 0.02]. Among subjects who achieved complete remission, homozygous G subjects had a time to progression of 250 days, whereas A-allele carriers had a time to progression of 1,118 days (HR, 4.5; 95% CI, 4.1-4.8, P = 0.04). The difference persisted after controlling for CD32 and CD16 polymorphisms. In patients who responded to rituximab used as first-line agent, a linear trend was observed among the C1qA([276]) genotypes, with homozygous A subjects achieving complete response at a higher rate compared with heterozygous or homozygous G subjects. CONCLUSIONS: Our findings indicate that polymorphisms in the C1qA gene may affect the clinical response and duration of response to rituximab therapy of follicular lymphoma. These results could have direct implications on designing antibodies with improved efficiency and enhance our understanding of the role of complement in monoclonal antibody therapy.
PURPOSE: Complement may play a role in the clinical response to rituximab and other monoclonal antibody-based therapies of cancer. The purpose of this study was to explore the relationship between the C1qA([276]) polymorphism and the clinical response to rituximab in patients with follicular lymphoma. EXPERIMENTAL DESIGN: Genotyping for C1qA([276A/G]) was done in 133 subjects with follicular lymphoma treated with single-agent rituximab, and correlation with clinical response was done using Cox regression analysis. RESULTS: Prolonged remission was observed among subjects that responded clinically to rituximab therapy and were carriers of the A allele compared with homozygous G subjects. Homozygous G subjects had a time to progression of 282 days, whereas A-allele carriers had a time to progression of 708 days [hazard ratio, (HR), 2.5; 95% confidence interval (95% CI), 2.0-3.1; P = 0.02]. Among subjects who achieved complete remission, homozygous G subjects had a time to progression of 250 days, whereas A-allele carriers had a time to progression of 1,118 days (HR, 4.5; 95% CI, 4.1-4.8, P = 0.04). The difference persisted after controlling for CD32 and CD16 polymorphisms. In patients who responded to rituximab used as first-line agent, a linear trend was observed among the C1qA([276]) genotypes, with homozygous A subjects achieving complete response at a higher rate compared with heterozygous or homozygous G subjects. CONCLUSIONS: Our findings indicate that polymorphisms in the C1qA gene may affect the clinical response and duration of response to rituximab therapy of follicular lymphoma. These results could have direct implications on designing antibodies with improved efficiency and enhance our understanding of the role of complement in monoclonal antibody therapy.
Authors: B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos Journal: J Clin Oncol Date: 1999-04 Impact factor: 44.544
Authors: P Colombat; G Salles; N Brousse; P Eftekhari; P Soubeyran; V Delwail; E Deconinck; C Haïoun; C Foussard; C Sebban; A Stamatoullas; N Milpied; F Boué; B Taillan; P Lederlin; A Najman; C Thièblemont; F Montestruc; A Mathieu-Boué; A Benzohra; P Solal-Céligny Journal: Blood Date: 2001-01-01 Impact factor: 22.113
Authors: J Golay; L Zaffaroni; T Vaccari; M Lazzari; G M Borleri; S Bernasconi; F Tedesco; A Rambaldi; M Introna Journal: Blood Date: 2000-06-15 Impact factor: 22.113
Authors: T A Davis; A J Grillo-López; C A White; P McLaughlin; M S Czuczman; B K Link; D G Maloney; R L Weaver; J Rosenberg; R Levy Journal: J Clin Oncol Date: 2000-09 Impact factor: 44.544
Authors: P R Taylor; A Carugati; V A Fadok; H T Cook; M Andrews; M C Carroll; J S Savill; P M Henson; M Botto; M J Walport Journal: J Exp Med Date: 2000-08-07 Impact factor: 14.307
Authors: C A Ogden; A deCathelineau; P R Hoffmann; D Bratton; B Ghebrehiwet; V A Fadok; P M Henson Journal: J Exp Med Date: 2001-09-17 Impact factor: 14.307
Authors: Laura M Rogers; Sarah L Mott; Brian J Smith; Brian K Link; Deniz Sahin; George J Weiner Journal: Clin Cancer Res Date: 2016-08-15 Impact factor: 12.531
Authors: Sean H Lim; Stephen A Beers; Ruth R French; Peter W M Johnson; Martin J Glennie; Mark S Cragg Journal: Haematologica Date: 2009-09-22 Impact factor: 9.941
Authors: B Namjou; C Gray-McGuire; A L Sestak; G S Gilkeson; C O Jacob; J T Merrill; J A James; E K Wakeland; Q-Z Li; C D Langefeld; J Divers; J Ziegler; K L Moser; J A Kelly; K M Kaufman; J B Harley Journal: Genes Immun Date: 2009-05-14 Impact factor: 2.676